# A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

Study · id `cardio:ct-nct07700875` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07700875](<https://clinicaltrials.gov/study/NCT07700875>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07700875

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 391 participants.

## Technical summary

Registry record NCT07700875. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2023-08-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 391 participants (enrolled count; ClinicalTrials.gov record NCT07700875, source copy `cardio:ctgov-nct07700875-2026-07-14`, retrieved 2026-10-26)
- Started: 2022-12-29 (actual) (ClinicalTrials.gov record NCT07700875, source copy `cardio:ctgov-nct07700875-2026-07-14`, retrieved 2026-10-26)
- Primary completion: 2023-08-20 (actual) (ClinicalTrials.gov record NCT07700875, source copy `cardio:ctgov-nct07700875-2026-07-14`, retrieved 2026-10-26)
- Completion: 2023-09-11 (actual) (ClinicalTrials.gov record NCT07700875, source copy `cardio:ctgov-nct07700875-2026-07-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07700875, source copy `cardio:ctgov-nct07700875-2026-07-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07700875-2026-07-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): QR12000 Compound Tablets 75 mg
- Intervention (Drug): QR12000 Compound Tablets 75 mg placebo
- Intervention (Drug): QR12000 Compound Tablets 150 mg
- Intervention (Drug): QR12000 Compound Tablets 150 mg placebo
- Intervention (Drug): QR01019 potassium salt 50 mg
- Intervention (Drug): QR01019 potassium salt 50 mg placebo
- Intervention (Drug): Sacubitril / valsartan 200 mg
- Intervention (Drug): Sacubitril / valsartan 200 mg placebo
- Intervention (Drug): Valsartan 160 mg
- Intervention (Drug): Valsartan 160 mg placebo
- Lead sponsor: Wuhan Createrna Science and Technology Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 2cdbb192fddf4d21050d2ce60b5b459b29934580cb0738270ce231f1b9fae8ef
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
